Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced two new manuscripts have been released, one as a peer reviewed publication in the Journal of Analytical Chemistry and one via preprint on ChemRxiv. The preprint has also been submitted for peer review.

In the first paper, titled “Exploration of Semiconductor Chip-Based Single-Molecule Protein Sequencing for Identification of Hemoglobin Variants”, the authors demonstrate the ability of Quantum-Si’s protein sequencing technology to directly identify clinically relevant hemoglobin variants from blood samples that are difficult to detect by traditional methods. The authors concluded that as the sequencing coverage increases, Quantum-Si’s protein sequencing technology will be well positioned as a tool in clinical proteomics and hemoglobinopathy research.

“We are excited to see Dr. Luo’s hemoglobin variant paper be published by the Journal of Analytical Chemistry”, said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “This paper does an excellent job showcasing the promise of our technology to extend beyond basic research and into the field of clinical proteomics, to be applied to address complex conditions like hemoglobinopathies that are not easily resolved using current technologies.”

In the second manuscript, released via preprint on ChemRxiv and titled “Optimization of Quantum-Si Platinum single-molecule protein sequencing platform towards improved complex-matrix protein identification”, the authors from the U.S. Naval Research Laboratory described a modified workflow to enable biological sample to result in under 24 hours. Furthermore, they demonstrated that this modified workflow could successfully identify long single-domain antibodies, shorter protein toxoids and detect proteins of interests from complex mixtures. Notably, the authors state that Quantum-Si currently presents the only benchtop, commercialized, single-molecule protein sequencing approach that eliminates arduous procedures typically associated with traditional methods.

“We are excited to see the results presented in the manuscript from the U.S. Naval Research Laboratory demonstrating a biological sample to result workflow in under 24 hours”, said Hawkins. “We appreciate the challenges of applying new technologies to complex real world problems like pathogens and toxin detection and look forward to continuing to support the U.S. Naval Research Laboratory in their endeavors.”

Hawkins continued, “These two papers are just a part of a strong pipeline of studies that we expect to be released during 2026. These papers demonstrate that the potential opportunity for our technology extends well beyond the basic research markets we operate in today with our first-generation technology. We believe that these studies also serve as additional data points that our Proteus platform strategy is well aligned with what the market needs to be able to fully realize the benefits of our proprietary single-molecule protein sequencing technology.”

For a listing of all publications and resources please follow this link.

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway, anticipated data and product launches (including Proteus), investor confidence in Quantum-Si and our strategic roadmap, and any financial guidance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth and retain its key employees; the Company’s ongoing leadership transitions and succession planning; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum protein sequencing instruments and kits and the Company’s other products (including Proteus) once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company's defense and initiation of litigation matters; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205739582/en/